Application and method of inducing immune rejection in tumor treatment

Abstract

The invention belongs to the technical field of biomedical engineering, and specifically relates to application and a method of inducing immune rejection in tumor treatment. The inducing immune rejection is the immune rejection induced by transplantation of allogeneic immune cells. The method for tumor treatment by inducing immune rejection specifically comprises sorting CD4+ T cells and injectingCD4+ cells. The immune rejection therapy provided by the present invention skillfully utilizes the immune rejection of body to realize the therapeutic effect on tumors, and a new method is provided for tumor treatment. The preparation of the cells required by the invention is simple, in vitro amplification culture is not needed to carry out, and allogeneic transplantation of exogenous cells can basically cause a recipient to produce immune rejection, so that the treatment has high effective rate and universality.

Description

technical field [0001] The invention belongs to the technical field of biomedical engineering, and in particular relates to the application and method of triggering immune rejection in tumor treatment. Background technique [0002] In recent years, the incidence and mortality of cancer have increased rapidly worldwide, becoming one of the main factors leading to population death in most regions. In 2018, the International Agency for Research on Cancer's research data on 36 types of tumors in 185 countries showed that there were about 18.1 million new cancer cases and 9.6 million cancer deaths worldwide, which is one of the problems that mankind needs to overcome. Traditional tumor treatment methods mainly include surgery, chemotherapy, radiotherapy, and tumor-targeted drug therapy. Surgery can directly remove the primary and metastatic lesions of some solid tumors, but it cannot fundamentally control the metastasis of tumor cells and tumor recurrence. Radiotherapy and chem...

AI Technical Summary

Problems solved by technology

However, there are still the following problems in this field: 1) Due to the characteristics of individual differences in patients, tumor heterogeneity, and differences in the tumor microenvironment, the overall effective rate of tumor immunotherapy is still relatively low, and the audience is relatively small; 2) Most of the treatments based on PD- 1 / PD-L1 combined drug strategy, there is still a lack of clinical evidence and basic theoretical support; 3) In addition to the PD-1 / PD-L1 signaling pathway, the research on other immune escape mechanisms is not deep enough, and the development of treatments for such targets Drugs are still a long way off

4) The current process of tumor immunotherapy is complicated and the cost of treatment is high

Therefore, the current research is mainly aimed at how to reduce immune rejection, develop some immunosuppressants, etc., and the positive effect of immune rejection on the body has not been found.

Moreover, there is currently no relevant research on the use of immune rejection to treat tumors. The present invention induces immune rejection in the body through the transplantation of heterologous immune cells for tumor treatment

Images